| Ms Kristina Simons, LCSW | |
|
100 S 1000 W, Tooele, UT 84074-4010 | |
| (888) 949-4864 | |
| Not Available |
| Full Name | Ms Kristina Simons |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 26 Years |
| Location | 100 S 1000 W, Tooele, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982683777 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 310140-3501 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Catholic Health Initiatives Colorado | 8022927342 | 998 |
News Archive
Halozyme Therapeutics, Inc. today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 with the active ingredient in NovoLog, accelerates insulin absorption and shortened its duration of action.
Ultra-high-field (7T) MRI can detect multiple sclerosis lesions better than MRI which can lead to possible earlier diagnosis and treatment, according to a new study by researchers from Ohio State University in Columbus, and Columbia University in New York.
Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.
To commemorate its fifth anniversary PLoS Neglected Tropical Diseases (NTDs) on Thursday "compiled editorials and research papers published over the last five years to create a collection called 'The Geopolitics of NTDs,'" the Global Network for Neglected Tropical Diseases' "End the Neglect" blog reports.
› Verified 3 days ago
| Entity Name | Physician Group Of Utah Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477676930 PECOS PAC ID: 8022032234 Enrollment ID: O20060113000886 |
News Archive
Halozyme Therapeutics, Inc. today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 with the active ingredient in NovoLog, accelerates insulin absorption and shortened its duration of action.
Ultra-high-field (7T) MRI can detect multiple sclerosis lesions better than MRI which can lead to possible earlier diagnosis and treatment, according to a new study by researchers from Ohio State University in Columbus, and Columbia University in New York.
Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.
To commemorate its fifth anniversary PLoS Neglected Tropical Diseases (NTDs) on Thursday "compiled editorials and research papers published over the last five years to create a collection called 'The Geopolitics of NTDs,'" the Global Network for Neglected Tropical Diseases' "End the Neglect" blog reports.
› Verified 3 days ago
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942903562 PECOS PAC ID: 8022927342 Enrollment ID: O20230615001995 |
News Archive
Halozyme Therapeutics, Inc. today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 with the active ingredient in NovoLog, accelerates insulin absorption and shortened its duration of action.
Ultra-high-field (7T) MRI can detect multiple sclerosis lesions better than MRI which can lead to possible earlier diagnosis and treatment, according to a new study by researchers from Ohio State University in Columbus, and Columbia University in New York.
Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.
To commemorate its fifth anniversary PLoS Neglected Tropical Diseases (NTDs) on Thursday "compiled editorials and research papers published over the last five years to create a collection called 'The Geopolitics of NTDs,'" the Global Network for Neglected Tropical Diseases' "End the Neglect" blog reports.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Kristina Simons, LCSW Po Box 572070, Murray, UT 84157-2070 Ph: (801) 263-7138 | Ms Kristina Simons, LCSW 100 S 1000 W, Tooele, UT 84074-4010 Ph: (888) 949-4864 |
News Archive
Halozyme Therapeutics, Inc. today announced results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 with the active ingredient in NovoLog, accelerates insulin absorption and shortened its duration of action.
Ultra-high-field (7T) MRI can detect multiple sclerosis lesions better than MRI which can lead to possible earlier diagnosis and treatment, according to a new study by researchers from Ohio State University in Columbus, and Columbia University in New York.
Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced treatment of the first cancer patient with Kolltan's lead drug candidate, KTN3379, as part of a Phase 1 clinical study evaluating safety, preliminary evidence of antitumor activity, and pharmacokinetics. KTN3379 is a human monoclonal antibody that blocks the activity of ErbB3, a member of the ErbB family of receptor tyrosine kinases.
To commemorate its fifth anniversary PLoS Neglected Tropical Diseases (NTDs) on Thursday "compiled editorials and research papers published over the last five years to create a collection called 'The Geopolitics of NTDs,'" the Global Network for Neglected Tropical Diseases' "End the Neglect" blog reports.
› Verified 3 days ago
Keri B Stone, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 71 N 50 W, Tooele, UT 84074 Phone: 801-990-4300 Fax: 801-967-2127 | |
Mr. Chris Corey Hakes, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 50 N Main St, Tooele, UT 84074 Phone: 801-414-3252 Fax: 801-967-2127 | |
Pamela Joan Bennett, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 100 S 1000 W, Tooele, UT 84074 Phone: 435-843-3520 | |
Hayley Baldwin Baldwin, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2356 N 400 E, Tooele, UT 84074 Phone: 435-850-2547 | |
Ms. Sarah Louise Debois, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 100 S 1000 W, Tooele, UT 84074 Phone: 435-843-3520 Fax: 435-843-3555 | |
Mr. Michal Allen Neff, LCSW, CSUDC Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 352 N Main St, Tooele, UT 84074 Phone: 435-200-3107 Fax: 435-291-3201 | |
Irene C Hopkins, CSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 754 N Main St, Tooele, UT 84074 Phone: 435-228-6523 |